A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy.

Pioneering success of antibodies targeting immune checkpoints such as PD-1 and CTLA4 has opened novel avenues for cancer immunotherapy. Along with impressive clinical activity, severe immune-related adverse events (irAE) due to the breaking of immune self-tolerance are becoming increasingly evident in antibody-based approaches. As a strategy to better manage severe adverse effects, we set out to discover an antagonist targeting PD-1 signaling pathway with a shorter pharmacokinetic profile.

Synthesis of monodisperse mesoporous TiO2 spheres with tunable sizes between 0.6 and 3.1 μm and effects of reaction temperature, Ti source purity, and type of alkylamine on size and monodispersity.

We report a novel method for synthesizing monodisperse mesoporous TiO(2) spheres (sizes = 0.6-3.1 μm) by hydrolysis of titanium isopropoxide (TIP) in a mixture of C(8)-C(16)n-alkylamine, water, and ethanol.